Financial News

Positive trial results for Novavax

Novavax Inc. (Nasdaq: NVAX) reported positive results from a Phase 2 clinical trial of its RSV F-protein recombinant nano particle vaccine candidate but the stock price tumbled $1.74 to close at $6.41.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback